DDInter1657 DDInter1680
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with [bortezomib] and [dexamethasone], is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells.[L7117,L7120,L10145] This condition is typically treated with high dose [bortezomib] and [dexamethasone] chemotherapy followed by an autologous stem-cell transplant. Other chemotherapies for multiple myeloma include [lenalidomide] and [dexamethasone], [thalidomide], and may include [melphalan] if the patient is not eligible for transplant. Selinexor was also granted accelerated approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that have gone through at least 2
The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain.
Smallpox (Vaccinia) Vaccine, Live {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Smallpox (Vaccinia) Vaccine, Live {u} may lead to a major life threatening interaction when taken with {v} Risankizumab
Smallpox (Vaccinia) Vaccine, Live may lead to a major life threatening interaction when taken with Cladribine
Smallpox (Vaccinia) Vaccine, Live may lead to a major life threatening interaction when taken with Risankizumab